[go: up one dir, main page]

NO20080437L - Lipaser til farmasoytisk anvendelse - Google Patents

Lipaser til farmasoytisk anvendelse

Info

Publication number
NO20080437L
NO20080437L NO20080437A NO20080437A NO20080437L NO 20080437 L NO20080437 L NO 20080437L NO 20080437 A NO20080437 A NO 20080437A NO 20080437 A NO20080437 A NO 20080437A NO 20080437 L NO20080437 L NO 20080437L
Authority
NO
Norway
Prior art keywords
lipases
pharmaceutical use
diabetes type
stable
protease
Prior art date
Application number
NO20080437A
Other languages
English (en)
Norwegian (no)
Inventor
Peter-Colin Gregory
Allan Svendsen
Kim Borch
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Publication of NO20080437L publication Critical patent/NO20080437L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20080437A 2005-06-24 2008-01-23 Lipaser til farmasoytisk anvendelse NO20080437L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500929 2005-06-24
PCT/DK2006/000352 WO2006136159A2 (fr) 2005-06-24 2006-06-16 Lipases a usage pharmaceutique

Publications (1)

Publication Number Publication Date
NO20080437L true NO20080437L (no) 2008-03-25

Family

ID=34956781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080437A NO20080437L (no) 2005-06-24 2008-01-23 Lipaser til farmasoytisk anvendelse

Country Status (17)

Country Link
US (1) US20090047266A1 (fr)
EP (1) EP1896577A2 (fr)
JP (1) JP2008546394A (fr)
KR (1) KR20080017025A (fr)
CN (1) CN101208429A (fr)
AR (1) AR053634A1 (fr)
AU (1) AU2006261442A1 (fr)
BR (1) BRPI0612274A2 (fr)
CA (1) CA2612648A1 (fr)
IL (1) IL187511A0 (fr)
MX (1) MX2007015472A (fr)
NO (1) NO20080437L (fr)
NZ (1) NZ563693A (fr)
RU (1) RU2007149045A (fr)
TW (1) TW200738256A (fr)
WO (1) WO2006136159A2 (fr)
ZA (1) ZA200710643B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
EP1896057A2 (fr) * 2005-06-24 2008-03-12 Novozymes A/S Amylases à usage pharmaceutique
MX2008000850A (es) 2005-07-29 2008-03-18 Solvay Pharm Gmbh Procedimientos para la fabricacion de polvo de pancreatina esterilizada.
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
BRPI0714241A2 (pt) * 2006-07-13 2013-03-12 Dsm Ip Assets Bv uso de uma amilase bacteriana, mÉtodos para preparar uma composiÇço, para aumentar o produÇço de leite de animais da subfamÍlia bovinae, para aumentar a espessura de gordura no dorso de animais da sbufamÍlia bovinae, para aumenantar o ganho de peso e/ou proporÇço de conversço de raÇço de animais da subfamÍlia bovinae, e para melhorar a digestibilidade aparente e/ou desaparecimento de mÁteria seca de gÊneros alimentÍcios em animais da subfamÍlia bovinae, e, uso de uma amilase bacteriana, mÉtodos para preparar uma composiÇço, para aumentar o produÇço de leite de animais da subfamÍlia bovinae, para aumentar a espessura de gordura no dorso de animais da subfamÍlia bovinae, para aumentar o ganho de peso e/ou proporÇço de conversço de raÇço de animais da subfamÍlia bovinae, e para melhorar a digestibilidade aparente e/ou desaparecimento de matÉria seca de gÊneros alimenticÍcios em animais da subfamÍlia bovinae, e, composiÇço
EP2455460A3 (fr) 2006-12-21 2012-12-26 Novozymes A/S Variantes de lipase pour utilisation pharmaceutique
JP2011505160A (ja) 2007-12-04 2011-02-24 ノボザイムス アクティーゼルスカブ 医薬用途のためのプロテアーゼ変異体
KR20100101106A (ko) * 2008-01-03 2010-09-16 애보트 프러덕츠 게엠베하 정제 미생물 리파제 과립들을 포함하는 약학 조성물 및 소화 장애들의 예방 또는 치료방법
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
GB2468629B (en) * 2008-06-08 2011-10-26 Tarig Sayed Mustafa Arbab Method, composition, device for the treatment of amylase malfunctions/inactivity in association with saccharides (mainly polysaccharides) based diseases
GB2465814B (en) * 2008-06-19 2011-10-26 Tarig Sayed Mustafa Arbab Method,composition and device for the treatment of enzymes and saccharides disorders
AU2009268585C1 (en) 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
WO2011000924A1 (fr) 2009-07-03 2011-01-06 Abbott Products Gmbh Amylase séchée par pulvérisation, préparations pharmaceutiques la comprenant et son utilisation
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
UY32948A (es) 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
ES2887576T3 (es) * 2011-12-29 2021-12-23 Novozymes As Composiciones detergentes con variantes de lipasa
WO2013102042A2 (fr) 2011-12-30 2013-07-04 Abbvie Inc. Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
GB201212932D0 (en) * 2012-07-20 2012-09-05 Dupont Nutrition Biosci Aps Method
GB201212934D0 (en) * 2012-07-20 2012-09-05 Dupont Nutrition Biosci Aps Method
CN103045559B (zh) * 2012-10-23 2014-05-14 浙江工业大学 疏绵状嗜热丝孢菌脂肪酶突变体、编码基因及其应用
CN104797590A (zh) 2012-11-01 2015-07-22 诺维信公司 用于去除dna的方法
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US10537122B2 (en) * 2013-12-17 2020-01-21 Alltech, Inc. Systems and methods for adjusting animal feed
US9672331B2 (en) * 2013-12-17 2017-06-06 Alltech, Inc. Systems and methods for computer models of animal feed
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
WO2019236717A1 (fr) * 2018-06-05 2019-12-12 Novozymes Bioag A/S Procédés de protection d'une plante contre les insectes nuisibles
CN115247166B (zh) * 2021-04-27 2025-11-25 南京百斯杰生物工程有限公司 一种蛋白酶突变体
AU2023272468A1 (en) 2022-05-14 2024-11-14 Novonesis Plant Biosolutions A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5892013A (en) * 1990-09-13 1999-04-06 Novo Nordisk A/S Lipase variants
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
EP1017794A1 (fr) * 1997-02-06 2000-07-12 Novo Nordisk A/S Conjugats polypeptide-polymere a groupes de fixation ajoutes et/ou retires
JP4723087B2 (ja) * 1998-11-27 2011-07-13 ノボザイムス アクティーゼルスカブ 脂質分解酵素変異体
DK1162995T3 (da) * 1999-03-17 2003-06-23 Solvay Pharm Gmbh Enzymer til behandling af diabetes mellitus type I
AU3420100A (en) * 1999-03-31 2000-10-23 Novozymes A/S Lipase variant
CN100455663C (zh) * 1999-03-31 2009-01-28 诺维信公司 脂肪酶变体
AR032392A1 (es) * 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
DE10260903A1 (de) * 2002-12-20 2004-07-08 Henkel Kgaa Neue Perhydrolasen
US20060251763A1 (en) * 2003-06-19 2006-11-09 Patkar Shamkant A Phospholipase variants

Also Published As

Publication number Publication date
BRPI0612274A2 (pt) 2016-09-06
WO2006136159A3 (fr) 2007-04-12
US20090047266A1 (en) 2009-02-19
RU2007149045A (ru) 2009-07-10
TW200738256A (en) 2007-10-16
EP1896577A2 (fr) 2008-03-12
AR053634A1 (es) 2007-05-09
ZA200710643B (en) 2008-11-26
NZ563693A (en) 2010-08-27
AU2006261442A1 (en) 2006-12-28
CA2612648A1 (fr) 2006-12-28
MX2007015472A (es) 2008-04-17
JP2008546394A (ja) 2008-12-25
KR20080017025A (ko) 2008-02-25
CN101208429A (zh) 2008-06-25
WO2006136159A2 (fr) 2006-12-28
IL187511A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20080437L (no) Lipaser til farmasoytisk anvendelse
NO20092729L (no) Lipasevarianter for farmasoytisk anvendelse
NO20080439L (no) Amylaser til farmasoytisk anvendelse
BRPI0510817A (pt) protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de uma doença
NO20080438L (no) Proteaser til farmasoytisk anvendelse
Araujo et al. Peptidase specificity characterization of C-and N-terminal catalytic sites of angiotensin I-converting enzyme
Lacroix et al. Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates
Baker et al. Quality control of mitochondrial proteostasis
PL1729797T3 (pl) Doustne kompozycje farmaceutyczne produktów zawierających lipazę, a zwłaszcza pankreatynę, zawierające środki powierzchniowo czynne
WO2009100348A3 (fr) Peptides et mimétiques peptidiques pour traiter les pathologies associées à une maladie oculaire
EP4413994A3 (fr) Fabrication d'enzymes de sulfatase lysosomales humaines hautement phosphorylées actives et leurs utilisations
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
RU2011102781A (ru) ПРИМЕНЕНИЕ Hsp70 В КАЧЕСТВЕ РЕГУЛЯТОРА ФЕРМЕНТАТИВНОЙ АКТИВНОСТИ
DK1162995T3 (da) Enzymer til behandling af diabetes mellitus type I
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
GB2497715A (en) Preparation and use of combination enzyme and gastriontestinal modulator delivery systems
MX2013000908A (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
EP1961816A4 (fr) Nouvelle enzyme extremement fonctionnelle ayant une specificite de substrat modifiee
TH88730A (th) ไลเปสสำหรับการใช้ทางเภสัชกรรม
Taylor et al. Cholinesterase confabs and cousins: approaching forty years
TH105721A (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
TH105721B (th) แวเรียนท์ของไลเปสสำหรับการใช้ทางเภสัชกรรม
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
WO2007057897A3 (fr) Composition pharmaceutical et procede de regulation de la proliferation cellulaire anormale

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application